S&P 500
7,656.98
+0.86% Fri
Executive dashboard
Nasdaq Comp.
26,333.04
+0.96% Fri
Dow
52,573.29
+0.98% Fri
Russell 2000
2,903.94
+0.45% Fri
VIX
15.84
−11.21% Fri
U.S. 2Y
4.63%
+7 bp day/day
U.S. 10Y
4.96%
near 5%
Dollar index
99.44
+0.32% live
WTI Oct.
$102.20
+2.15% live
Gold Dec.
$4,369.10
−0.90% vs Fri settle
S&P future
7,622.00
−0.49% live
Nasdaq future
29,020
−1.25% live
| Region / index | Level | Move | Session status at cutoff |
|---|---|---|---|
| Nikkei 225 | 63,570.44 | −0.69% | Near close, 15:17 JST; not final. Quote |
| Kospi | 6,681.75 | −3.30% | Near close, 15:12 KST; AI/chip-heavy weakness. Quote |
| Hang Seng | 24,888.20 | +0.33% | Live 14:17 HKT; afternoon session ongoing. Quote |
| Shanghai Composite | 3,880.86 | −0.19% | Live 14:17 CST; session ongoing. Quote |
| Euro Stoxx 50 | 6,325.13 | +0.90% Fri | Europe pre-open; prior cash close only. Quote |
| DAX / FTSE 100 / FTSE MIB | 25,568.56 / 10,650.40 / 52,512 | +0.82% / +0.39% / +1.36% Fri | Prior cash closes; no fabricated early print. DAX · FTSE · MIB |
Oil shock is back in charge
WTI above $102 and Brent near $107 after Gulf–Iran Hormuz talks were postponed and a Saudi pipeline was shut after damage. This is an inflation, margin and rate shock—not merely an energy-sector move. CNBC
AI duration is de-risking
Nasdaq futures lag at −1.25%; Korea's chip-heavy Kospi fell 3.30%. Bloomberg and CNBC both connect part of the move to frontier-lab calls to slow AI development; this is a sentiment/regulatory-duration catalyst, not evidence that deployed AI demand vanished. Bloomberg · CNBC
Fed event risk arrives tomorrow
The FOMC meets Sep. 15–16 with a new Summary of Economic Projections. Official 2Y/10Y yields were already 4.63%/4.96% Friday; a stronger dollar and higher oil tighten conditions before the decision. Federal Reserve
Market drivers
Macro, rates and central banks
- Friday rebound, Monday reset: all four U.S. cash indices gained Friday and VIX fell, but futures now give back part of that relief; NQ underperformance makes the signal growth-duration negative.
- Yield pressure: the official Treasury curve's latest available observation is Sep. 11: 2Y 4.63%, 10Y 4.96%. The market enters the FOMC with little cushion against a 5% 10Y. U.S. Treasury
- No major U.S. release today: the next BLS event is import/export prices Sep. 16 at 08:30 ET—14:30 CEST, well after this report. BLS calendar
Geopolitics, earnings and rotation
- Hormuz risk: stalled diplomacy and infrastructure damage push crude higher; airlines, transports, consumers and long-duration equities face the adverse side while energy cash flows may benefit. Current report
- AI-policy narrative: calls by OpenAI/Anthropic leaders to slow frontier development introduce timing and regulation uncertainty. They do not amend public-company guidance; no such inference is made. CNBC
- Verified unusual Friday move: ORCL opened $164.43, touched $166 and closed $150.28 on 79.5M shares; volume was 3.31× its trailing-20-session average in the retrieved chart. The tape rejected the earnings gap. History · 10-Q
Theme dashboards
Fundamentals intact; multiple compression risk rises
- Friday leaders: ANET +5.61%, VRT +3.60%, QCOM +2.88%, AMD +2.49%. Laggards: ORCL −1.74%, NVDA −0.03%.
- Current catalyst: AI-slowdown commentary plus NQ −1.25% and Kospi −3.30% create a negative opening setup.
- Primary evidence: Nvidia's latest quarter reported $96.2B revenue, +106% y/y, while excluding China data-center compute revenue from outlook. Demand is real, but concentration, financing, export and valuation risks remain. Nvidia SEC exhibit
Funding and M&A obscure organic economics
- 20-session laggards: QBTS −19.62%, IONQ −18.30%, RGTI −17.99%, QUBT −10.43% despite small Friday gains in three names. IONQ quote
- IonQ caveat: new $450M–$460M 2026 revenue guidance includes SkyWater from July 31; it is not a clean quantum-organic growth measure. IonQ
- Risk: pre-profit economics, integration, government-milestone dependence, technical validation, dilution and gap/squeeze risk dominate. No long setup clears the evidence bar today.
VKTX readout window is open, still undated
- Tape: VKTX −5.89% over five sessions and −4.75% below its 20-day average; NVO fell 9.35% over five sessions. Price is not clinical evidence.
- Study: Viking's randomized, double-blind Phase 1 maintenance study has ~180 adults with obesity; safety/tolerability/PK are objectives and weight change is exploratory across weekly, every-other-week and monthly regimens. Results are guided for Q3. Viking IR
- Runway/regulatory: June cash and investments were ~$502M; current liabilities ~$110M. Phase 3 injectable trials are enrolled, but the maintenance study itself is not registrational. Safety, durability, competition, manufacturing and dilution remain decisive.
Ranked conditional ideas
Bullish list: no compelling actionable opportunity at 08:30 CEST. ANET and QCOM retain constructive technical evidence but move to watch because individual U.S. premarket prices are not yet available, NQ futures are −1.25%, oil is above $102 and the FOMC begins tomorrow. This avoids manufacturing a fill before price discovery.
Bearish / short / avoid
ORCL · Oracle
Exchange/risk: NYSE; mega-cap cloud; extreme event, capex and debt sensitivity. Classification: avoid; confirmation-only bearish. Applicable horizon: day trade and 1–4 weeks; not a 3–12+ month structural short. Direction: uncertain; short losses can be unlimited.
Thesis/catalyst/evidence: Friday's earnings gap reversed from $166 to a $150.28 close on 3.31× 20-day volume; risk-off NQ futures add pressure. Counterargument: OCI demand and contracted backlog can fuel a violent rebound; backlog is not yet revenue, margin or cash.
Entry/confirmation: only after a failed $152.94 reclaim and break/hold below $149.84. Invalidation/downside: bearish case weakens above $159.24; no fixed downside target is asserted. Key risks: squeeze, execution, debt/credit, capex, power/construction, customer concentration, FOMC. Borrow availability and fees are unknown. SEC filing
IONQ · IonQ
Exchange/risk: NYSE; high-volatility, acquisition/dilution and technical risk. Classification: avoid; bearish trigger only. Applicable horizon: day trade and 1–4 weeks only. Direction: uncertain; short losses can be unlimited.
Thesis/catalyst/evidence: $36.75 is 10.06% below its 20-day average and the sector is broadly weak; expanded guidance includes acquired SkyWater. Counterargument: government awards, integration news and technical milestones can generate abrupt squeezes.
Entry/confirmation: below $36.33 after a failed $36.78 reclaim. Invalidation/downside: close above $38.14; downside is undefined. Key risks: acquisition accounting, technical success, contracts, burn, dilution, warrants, gaps and liquidity. Sep. 29/30 warrant mechanics may distort trading; borrow terms are unknown. Primary release · SEC 8-K
NVO · Novo Nordisk ADR
Exchange/risk: NYSE ADR; large-cap pharma with FX, pricing and clinical risk. Classification: avoid / breakdown watch. Applicable horizon: 1–4 weeks; no automatic long-term short. Direction: uncertain.
Thesis/catalyst/evidence: $43.07 Friday, −2.14% while S&P gained 0.86%; five-session return −9.35% and 6.23% below its 20-day average. Counterargument: established semaglutide cash flows and Sep. 29 EASD evidence flow can reverse sentiment.
Entry/confirmation: avoid; bearish only on a close below $42.72. Invalidation/downside: regain $44.56; stronger above $46.60. Key risks: positive clinical evidence, access/pricing, supply, patents, FX, competition and squeeze. Borrow availability/fees unknown. Quote · Novo/EASD
Watchlist · confirmation required
QCOM · Qualcomm
Exchange/risk: Nasdaq; large-cap semiconductor, high customer/execution risk. Classification: bullish watch—not a current long. Applicable horizon: day/1–4 weeks; 3–12+ months only as economics mature. Direction: uncertain.
Thesis/catalyst/evidence: Friday +2.88%; five-session +7.95%, 9.06% above 20-day average. Amazon collaboration covers custom inference and 1.6T optical links. Counter: economics/timing remain incomplete and NQ is risk-off. Entry/confirmation: close above $185.46 with chip breadth after FOMC. Invalidation/downside: close below $175.74, then $172 risk. Risks: concentration, warrant dilution, competition, margins, exports and rates. SEC 8-K
ANET · Arista Networks
Exchange/risk: NYSE; large-cap, high-beta AI networking. Classification: bullish breakout watch. Applicable horizon: day/1–4 weeks; long term only after valuation review. Direction: uncertain.
Thesis/evidence: +5.61% Friday, closed $199.59 and 3.33% above 20-day average. Counter: 20-session return remains −1.98%, Friday volume was only 0.89× the 20-day average, and today's AI tape is adverse. Entry/confirmation: close above $200.25 with positive networking breadth. Invalidation/downside: below $192.10, then $188.99. Risks: hyperscaler concentration, capex pause, competition, exports, supply, valuation and rates. Price history · SEC submissions
VRT · Vertiv
Exchange/risk: NYSE; high-beta large-cap infrastructure. Classification: reversal watch. Applicable horizon: day/1–4 weeks. Direction: uncertain.
Thesis/evidence: structural data-center power/cooling demand and Friday +3.60%. Counter: five-session −4.38%, 20-session −10.45%, still 3.49% below 20-day average. Entry/confirmation: close above $258.78; stronger above $263, with NQ stabilization. Invalidation/downside: below $251.84, then $248.13. Risks: valuation, order conversion, execution, input/energy costs and rates. Price history
VKTX · Viking Therapeutics
Exchange/risk: Nasdaq; small-cap, pre-revenue clinical biotech; binary and dilution risk. Classification: event watch, not a pre-data long. Applicable horizon: 1–4 weeks around data; 3–12+ months only after full safety/efficacy/regulatory analysis. Direction: uncertain.
Thesis/catalyst: Q3 Phase 1 maintenance data; ~180 randomized adults, safety/tolerability/PK objectives and exploratory weight durability. June cash/investments ~$502M. Counter: undated, limited sample, non-registrational endpoints, first-half burn and share growth. Entry/confirmation: acceptable safety plus maintained loss and close above $33.05/$33.68. Invalidation/downside: weak durability, safety/discontinuation signal, delay or close below $31.70. Risks: GI/safety, statistics, regulatory path, LLY/NVO competition, manufacturing, cash runway and dilution. Viking IR
RGTI · Rigetti Computing
Exchange/risk: Nasdaq; small-cap, pre-profit, extreme technical/dilution risk. Classification: catalyst watch only. Applicable horizon: day/1–4 weeks. Direction: uncertain.
Thesis/catalyst: a signed U.S. Commerce agreement targets up to $100M over three years for electronics, cryogenic and fabrication work. Counter: funding is milestone/execution dependent, government equity dilutes holders, and the stock remains 17.99% lower over 20 sessions. Entry/confirmation: close above $15.81; stronger above $16.40. Invalidation/downside: below $15.08, then $14.84. Risks: fidelity/roadmap failure, appropriations, burn, dilution, liquidity and gaps. SEC 8-K
Scores are 0–100. Higher Risk means riskier; Thesis Confidence grades evidence quality, not probability of profit. Entries are confirmation rules, not guaranteed fills.
Changes versus the 2026-09-13 report
- Regime downgraded: neutral/event-heavy → risk-off/event-heavy because S&P futures are −0.49%, Nasdaq futures −1.25%, WTI +2.15%, DXY +0.32% and Korea −3.30%.
- Friday levels unchanged: no U.S. cash session has occurred since the prior report. The new information is live futures, Asian trading and overnight news—not invented stock prints.
- Bullish calls reduced to zero: ANET and QCOM move from conditional bullish rankings to watchlist until U.S. price discovery and post-FOMC confirmation.
- Bearish ordering retained: ORCL, IONQ and NVO remain confirmation-only avoids; opportunity scores edge up modestly, but risks remain 93–100.
- Primary-filings check: SEC submissions through cutoff show no new material operating filing after Sep. 11 among the reviewed NVDA/ANET/QCOM/ORCL/IONQ/RGTI/VKTX/LLY/NVO set; the latest entries were predominantly Forms 4/144. Example: NVDA submissions
- New overnight catalysts: stalled Hormuz talks and AI-slowdown commentary now dominate Monday's setup.
Important 7–30 day catalysts
Sep. 15–16 — FOMC; decision and SEP on Sep. 16
Primary macro catalyst for yields, dollar and duration equities. No guaranteed outcome is assumed. Federal Reserve
Primary macro catalyst for yields, dollar and duration equities. No guaranteed outcome is assumed. Federal Reserve
Sep. 16 · 14:30 CEST — U.S. import/export prices and retail sales
External-price and demand evidence arrives before the Fed decision; 08:30 Italy reports cannot include it. BLS · Census
External-price and demand evidence arrives before the Fed decision; 08:30 Italy reports cannot include it. BLS · Census
Sep. 17–18 — housing/claims/Philly Fed, then industrial production
Growth and capacity signals relevant to cyclicals and power/data-center supply chains. Fed G.17
Growth and capacity signals relevant to cyclicals and power/data-center supply chains. Fed G.17
Sep. 23 — FDA genetics-device advisory panel
No direct peptide-thesis catalyst identified; included for biotech risk calendar discipline. FDA also lists a pediatric committee Sep. 16. FDA
No direct peptide-thesis catalyst identified; included for biotech risk calendar discipline. FDA also lists a pediatric committee Sep. 16. FDA
Sep. 24 and Sep. 30 — BEA macro releases
International transactions Sep. 24; GDP third estimate, profits and August income/outlays Sep. 30. BEA
International transactions Sep. 24; GDP third estimate, profits and August income/outlays Sep. 30. BEA
By Sep. 30, undated — VKTX maintenance readout
Issuer-guided Q3 window; safety/tolerability/PK objectives with exploratory weight change. No exact date or result is assumed. Viking
Issuer-guided Q3 window; safety/tolerability/PK objectives with exploratory weight change. No exact date or result is assumed. Viking
Sep. 28–Oct. 2 — EASD 2026; Novo symposium Sep. 29
Potential semaglutide/amylin evidence flow; unpublished outcomes are not assumed. Novo/EASD
Potential semaglutide/amylin evidence flow; unpublished outcomes are not assumed. Novo/EASD
Sep. 29/30 — IONQ warrants cease trading / expire
Capital-structure flows can distort the tape. SEC terms
Capital-structure flows can distort the tape. SEC terms
Bottom line by horizon
Day trade
Stance: defensive; wait for European and U.S. price discovery. Do not chase gaps. Favor only confirmed breakdowns in ORCL/IONQ or reclaim setups in QCOM/ANET after breadth confirms.
Biggest risk: headline reversal in Hormuz diplomacy or AI commentary. Regime invalidation: ES recovers Friday's 7,659.5 settlement while oil falls back below $100 and NQ closes its underperformance.
1–4 week swing
Stance: smaller exposure through FOMC; prioritize balance sheets, cash conversion and relative strength over pre-profit duration. Preserve optionality for post-decision entries.
Biggest risk: oil-driven inflation and a 10Y break above 5%. Invalidation: 10Y sustainably below 4.80%, easing oil and broad indices above Sep. 4 closes would upgrade the setup.
3–12+ month investment
Stance: AI infrastructure demand evidence remains strong, but require revenue conversion, margins and FCF. Quantum requires independently validated utility and unit economics; peptide biotech requires complete efficacy/safety and regulatory/runway work.
Biggest risk: capital-cost shock, concentration, dilution, technical or clinical failure. Invalidation: sustained deterioration in orders, cash generation, roadmap evidence or clinical benefit—not one volatile session.
Data quality, sources and limitations
- Live research performed: Yahoo chart APIs for U.S./global indices, futures, commodities and 13 thematic stocks; CNBC market RSS and current articles; Bloomberg cross-check; official Treasury, Fed, BLS, BEA and FDA pages; SEC submissions/filings for nine companies; and primary IonQ/Viking/Qualcomm/Rigetti/Oracle materials. More than five meaningful retrieval calls were completed.
- Timestamps: futures/commodities/FX and Asian levels are from Yahoo chart metadata around 08:12–08:22 CEST. U.S. stocks and cash indices are Sep. 11 closes. Treasury yields are official Sep. 11 observations. European figures are Sep. 11 closes because cash markets had not opened.
- Cross-checks: WTI/Brent direction and levels were checked against CNBC; U.S. Friday index closes against CNN/CNBC-style market data; FOMC and release dates against official agencies; thematic claims against filings or issuer releases.
- Limitations: Yahoo/Firecrawl rate-limited several parallel requests; direct terminal retrieval succeeded for the quote set. The Rigetti IR host was blocked by one extractor, so the SEC 8-K was used. The supplied ClinicalTrials.gov ID resolved to an unrelated anesthesia study and was discarded; Viking's issuer description is used and explicitly labels endpoints. No rating change from thin secondary headlines is treated as fact. No U.S. individual premarket prices existed at 02:30 ET.